Edwards Lifesciences (EW) Revenue — Quarter Ended Sep 30, 2023
Revenue for the quarter decreased compared to the immediately preceding quarter and also declined when measured against the same quarter one year earlier. The company reported a lower top line in both comparisons.
Key takeaway
Quarter ended Sep 30, 2023 · FY2023 Q3
Revenue for the quarter decreased compared to the immediately preceding quarter and also declined when measured against the same quarter one year earlier. The company reported a lower top line in both comparisons.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.2B
Revenue reported for this quarter.
Quarter-over-quarter
-7.7%
Change from the immediately preceding quarter.
Year-over-year
-8.2%
Change from the comparable year-ago quarter.
Trailing four quarters
$4.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $429.9M | -67.7% |
| Mar 31, 2023 | $1.2B | -8.9% |
| Jun 30, 2023 | $1.3B | -4.5% |
| Sep 30, 2023 | $1.2B | -8.2% |
Revenue performance
The reported revenue moved downward from the prior quarter, reflecting a sequential contraction. On a year-over-year basis, revenue was also lower, indicating a decline from the comparable period in the prior year.
Quarterly comparison
Compared with the immediately preceding quarter, revenue fell. Versus the same quarter one year earlier, revenue also decreased, marking a decline in both sequential and annual comparisons.
What to watch
The trend shows consecutive quarterly declines, suggesting continued revenue pressure.